

Prevnar 13[®] (PCV13)

Age at First Dose	Total # of Doses	Schedule
2-6 months	4	<ul style="list-style-type: none"> ▪ 2, 4, and 6 months of age, 8 weeks apart ▪ Booster dose at age 12-15 months
7-11 months	3	<ul style="list-style-type: none"> ▪ 2 doses, 8 weeks apart ▪ Booster dose at 12-15 months, with a 2-month interval after the second dose
12-23 months	2	<ul style="list-style-type: none"> ▪ 2 doses, 6-8 weeks apart
24-59 months (healthy children)	1	<ul style="list-style-type: none"> ▪ 1 dose for healthy children
24-71 months (high risk)	2	<ul style="list-style-type: none"> ▪ 2 doses, 6-8 weeks apart if child is at high risk



Dosage and Administration

- 4-dose immunization series (depending on the age of child at time of first dose).
- Administered at 2, 4, 6, and 12-15 months of age.
- 0.5 mL intramuscular (IM) injection only.
- Preferred sites for administration are the anterolateral aspect (vastus lateralis muscle) of the thigh in infants or the deltoid muscle of the upper arm in toddlers and young children.

Schedule:

- Recommended schedules for pneumococcal conjugate vaccine vary with the child's age and the presence of underlying conditions.
- Administer 1 dose of pneumococcal conjugate vaccine to all healthy children aged 24-59 months who have not received at least 1 dose of PCV on or after age 12 months.
- Children aged 24-59 months with underlying medical conditions should receive 1 dose of PCV13 if 3 doses were received previously.

PCV13 Indications and Usage:

- Approved for use in children 6 weeks thru 5 years of age (prior to 6th birthday).
- Recommended by ACIP for all children aged 2-59 months.
- Indicated for children 6 years thru 18 years with high risk conditions who are at increased risk for IPD because of sickle cell disease, HIV infection or other immunocompromising conditions, cochlear implants or cerebrospinal fluid leaks, regardless of whether they have previously received PCV7 or PPSV23.
- Indicated for active immunization for the prevention of invasive pneumococcal disease (IPD) caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
- Indicated for the prevention of otitis media caused by *Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.
- Can be administered with other vaccines given at the same time.

Vaccine Storage and Handling

- Store Prevnar in the refrigerator (40°F) (aim for 40°F).
- **Do not freeze** – discard if vaccine has been frozen.

Transition from PCV7 to PCV13 among infants and children according to number of previous PCV7 doses.

Primary Infant Series			Booster Dose	Supplemental PCV13 Dose
2 months	4 months	6 months	≥ 12 months*	14-59 months**
PCV7	PCV13	PCV13	PCV13	---
PCV7	PCV7	PCV13	PCV13	---
PCV7	PCV7	PCV7	PCV13	---
PCV7	PCV7	PCV7	PCV7	PCV13

*No additional PCV13 doses are indicated for children 12 through 23 months who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.

**For children with underlying medical conditions, a supplemental PCV13 dose is recommended through 71 months of age.

PCV13 Supplemental Dose		
Age at examination (months)	Vaccination history: total number of PCV7 and/or PCV13 doses previously received	Recommended PCV13 Regimen
Healthy children 24 through 59 months	Unvaccinated or any incomplete schedule	1 dose, ≥ 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate, complete PCV7 schedule	1 supplemental dose, ≥ 8 weeks after the most recent dose and another dose ≥ 8 weeks later
Children 24 through 71 months with underlying medical conditions	Unvaccinated or any incomplete schedule of <3 doses	2 doses, one ≥8 weeks after the most recent dose and another dose ≥8 weeks later
	Any incomplete schedule of 3 doses	1 dose, ≥ 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, ≥8 weeks after the most recent dose

Contraindications

- A severe allergic reaction (e.g. anaphylaxis) to any component of Prevnar 13, Prevnar (Pneumococcal 7-Valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) or any diphtheria toxoid-containing vaccine.

Precautions

- **Premature infants:** Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision to administer should be based on consideration of the individual infant’s medical status, and the potential benefits and possible risks of vaccination.

Adverse Reactions

- **Local (injection site):** redness, swelling, tenderness.
- **Systemic (general):** fever, decreased appetite, irritability, increased sleep, decreased sleep.

